

TOBI

(tobramycin powder for inhalation)

Effective Date: 4/22/14

Date Developed: 4/9/14 by Dr. Robert Sterling

Last Approval Date: 1/26/16, 1/24/17, 1/22/19, 2/18/20

(Archive Date: 1/1/18)

Unarchived Date: 1/22/19 (Formulary Exclusion – For Exception Review Use Only)

Tobramycin powder is an aminoglycoside antibiotic which interferes with bacterial protein synthesis by binding to 30S and 50S ribosomal subunits, resulting in a defective bacterial cell membrane.

Authorization Criteria: management of cystic fibrosis patients with *Pseudomonas aeruginosa* in patients six years of age or older

Dosing: inhalation of the contents of four 28 mg TOBI capsules twice-daily for 28 days using the Podhaler device.

How Supplied: 28 mg capsules

Contraindications/Warnings: FOR USE WITH THE PODHALER DEVICE ONLY; contraindicated with a known hypersensitivity to any aminoglycoside; use with caution in patients with renal, auditory, vestibular dysfunction or neuromuscular disorders; may cause bronchospasm

Major Adverse Reactions: cough; dyspnea; oropharyngeal pain

Major Drug Interactions: diuretics may enhance potential toxicity

REFERENCES

Sagel SD, Gibson RL, Emerson J, et al. Impact of *Pseudomonas* and *Staphylococcus* infection on inflammation and clinical status in young children with cystic fibrosis. *J Pediatr* 2009; 154:183.

Emerson J, Rosenfeld M, McNamara S, et al. *Pseudomonas aeruginosa* and other predictors of mortality and morbidity in young children with cystic fibrosis. *Pediatr Pulmonol* 2002; 34:91.

Hyatt AC, Chipps BE, Kumor KM, et al. A double-blind controlled trial of anti-*Pseudomonas* chemotherapy of acute respiratory exacerbations in patients with cystic fibrosis. *J Pediatr* 1981; 99:307.

Lindsay CA, Bosso JA. Optimisation of antibiotic therapy in cystic fibrosis patients. Pharmacokinetic considerations. Clin Pharmacokinet 1993; 24:496.

Szaff M, Høiby N, Flensburg EW. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand 1983; 72:651.

Ryan G, Mukhopadhyay S, Singh M. Nebulised anti-pseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2003; :CD001021.

Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340:23.

Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002; 121:55.

Burns JL, Van Dalftsen JM, Shawar RM, et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999; 179:1190.

Bowman CM. The long-term use of inhaled tobramycin in patients with cystic fibrosis. J Cyst Fibros 2002; 1:194.

Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros 2011; 10:54.

Parkins MD, Elborn JS. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis. Expert Rev Respir Med 2011; 5:609.

Revision History:

Date Approved by P&T Committee: 4/22/14

Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD

Date Approved by P&T Committee: 01.27.15

Date Reviewed/No Updates: 1/26/16 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/26/16

Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/24/17

Date Reviewed/Archived: 1/1/18 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/23/18

Date Reviewed/No Updates/Date Unarchived: 1/22/19 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/22/19

Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 2/18/20

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
1/24/17	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/1/18	No	Catherine Sanders, MD; Robert Sterling, MD	Archived – excluded from the Formulary effective 1/1/18
1/22/19	Yes	Catherine Sanders, MD; Robert Sterling, MD	Unarchived – Formulary Exclusion – For Exception Review Use Only Annual Review
2/18/20	No	Howard Taekman, MD; Robert Sterling, MD	Annual review